论文部分内容阅读
Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal
【作 者】
：
【机 构】
：
The Biotechnology Centre and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, Universi
【出 处】
：
2015年临床肿瘤学新进展学术研讨会
【发表日期】
：
2015年3期
其他文献
Randomized phase Ⅱ, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (
会议
Final clinical results of a randomized phase Ⅱ international trial of everolimus vs. sunitinib in pa
会议
A randomized phase Ⅱ study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimu
会议
Docetaxel and/or zoledronic acid for hormone-na(i)ve prostate cancer: First overall survival results
会议
Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respo
会议
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or re
会议
CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN a
会议
会议